Cellares

Cellares CEO and Co-Founder, Fabian Gerlinghaus, will present at the Biomanufacturing World Summit on Thursday, November 21st at 7:45 AM PT. His talk, "The Coming Patient Treatment Crisis," will explore critical challenges patients face in accessing cell therapies. Don’t miss this opportunity to hear from a prominent biotech leader and discover how Cellares’ pioneering technological approach to high-throughput manufacturing will enable cell therapy developers to meet the full demand for their life-saving treatments. For further details on Cellares' cutting-edge automated cell therapy manufacturing technology, visit cellares.com/technology.

??Breaking Leadership News from Cellares! ?? We are pleased to announce the appointment of Ossama Eissa as Cellares’ new Chief Operating Officer. With a background spanning Novartis, Lonza Biologics, and Legend Biotech, Eissa’s experience will support the expansion of Cellares IDMO Smart Factories in the United States, Europe, Japan, and other key international markets, deliver on existing commercial contracts, and meet rapidly growing customer demand for our manufacturing services. Eissa brings 20+ years of biopharma leadership experience to Cellares, notably as the site head for commercial-scale manufacturing of two FDA-approved CAR-T cell therapies, Carvykti? at Legend Biotech and Kymriah? at Novartis. Cellares is committed to making cell therapies more accessible and ensuring patients facing cancer and autoimmune disorders receive timely treatment. Eissa’s leadership will help us scale cell therapy manufacturing to meet global demand. Welcome, Ossama Eissa, to the Cellares team! Read more here: https://lnkd.in/gpVkiFBk #Leadership #HealthcareInnovation #CellTherapy #Cellares #PatientAccess #GlobalExpansion

John Tomtishen, Cellares’ SVP of Operations & GM, NJ IDMO, will be joining a panel of cell and gene therapy industry experts, including Alison Moore, Chief Technical Officer, Codexis, Inc.; Brian Riley, Chief Manufacturing Officer, Beam Therapeutics; Harish Santhanam, Vice President Cell Therapy Technical Operations, Bristol Myers Squibb; and Christine Sheaffer, Vice President Manufacturing & Supply, Spark Therapeutics, Inc., in a discussion covering The Evolution of Innovative Modalities —Defining the Future of Manufacturing & Development at Biomanufacturing World Summit. Don’t miss the opportunity to hear these leading voices discuss topics including scaling up manufacturing to meet global patient demand, the evolution of regulatory pathways, and next-generation cell and gene therapy manufacturing technologies. Please join us on Tuesday, Nov 19th at 5pm PT for what is sure to be an educational and thought-provoking discussion!

Join us as we explore a lively discussion focused on cell and gene therapy topics in a recent Buy, Sell, Hold panel featured on BioPharm International. In part 1, Cellares co-founder and CEO, Fabian Gerlinghaus, joins a notable group of experts, including Dr. Claudia Zylberberg, Board Chair and Co-Founder of Arscience Biotherapeutics & Board Chair and Co-Founder of Akron Biosciences, and Benjamin McLeod, Director, Cell & Gene Therapy Segment, NanoMosaic, to discuss critical topics ranging from the importance of focusing on orphan diseases to the impact AI and quantum computing will have on innovation. Don't miss out on this valuable exchange of knowledge and innovation. View the full panel discussion here: https://lnkd.in/e5kRVRwV

?? We are pleased to announce that Cellares has been selected as a finalist in the 2024 Fierce Life Sciences Innovation Awards, Technology Category! ?? This recognition underscores our commitment to revolutionizing cell therapy manufacturing with innovative solutions like the Cell Shuttle and Cell Q. Winners will be featured in the Innovation Report on December 2nd. Stay tuned! Click here to see the full list of finalists and learn more about the awards: https://lnkd.in/epdDMtPC #BiotechInnovation #LifeSciences #CellTherapy #FierceLifeSciencesInnovationAwards #FierceInnovationAwards

Fabian Gerlinghaus, CEO and Co-Founder of Cellares, will be presenting at Meeting on the Mesa on Tuesday, Oct 8th at 3:15 PM MST. His presentation, "The Coming Patient Treatment Crisis", will address some of the most pressing issues regarding patient access to cell therapies faced by the industry today. Don't miss this chance to gain insights from a leading voice in the biotech industry and learn about Cellares’ innovative manufacturing solutions that could enable cell therapy developers to meet the total patient demand for their life-saving treatments. To learn more about Cellares’ innovative manufacturing technology, please visit cellares.com/technology

Cellares is honored to be a finalist in the Emerging Innovation category at the 21st annual California Life Sciences Pantheon Awards! ?? ??? Your vote can help us win! Cast your vote now at the link below. Winners will be announced live on November 7th in San Francisco. ?? ?? Vote Here: https://bit.ly/4guw3n8

Cellares is thrilled to be attending the annual Meeting on the Mesa from October 7th - 9th! If you're attending, we’d love to meet with you! Reach out via the event's partnering app or email us at [email protected] to schedule time with the team. Learn more about our IDMO offerings and how we're revolutionizing cell therapy manufacturing. Visit us at www.cellares.com/services. #MeetingOnTheMesa #CellTherapy #BiotechInnovation

I'm grateful to Matt Fazelpoor @ NJBIZ for the opportunity to speak about Cellares' first commercial-scale IDMO Smart Factory to Bridgewater, NJ. Great piece! Read the full article here: https://lnkd.in/d3xRWVFe

Cellares will be exhibiting at the 9th annual CAR-TCR Summit in Boston from Tuesday, September 17th - Friday, September. 20th. Please join us at booth 21 to learn how our Industry 4.0 approach is poised to revolutionize cell therapy manufacturing. Interested in meeting with us? Reach out via the event app or contact us directly at [email protected]. Let's discuss how we can accelerate access to life-saving cell therapies together! #CARTCRSummit #CellTherapy #Biotechnology #CGT